Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 168,130	$ 179,338
Accounts receivable	78,270	60,587
Inventories	66,030	14,643
Income tax receivable, net	16,674	5,651
Prepaid expenses and other current assets	16,345	12,896
Total current assets	345,449	273,115
Property, plant and equipment, net	302,455	264,240
In process research and development	50,300	41,800
Intangible assets, net	66,678	30,148
Goodwill	47,188	13,954
Deferred tax assets - long-term, net	16,411	0
Other assets	8,768	3,373
Total assets	837,249	626,630
Current liabilities:
Accounts payable	36,968	27,521
Accrued expenses and other current liabilities	2,957	1,252
Accrued compensation	23,044	24,615
Contingent purchase consideration, current portion	3,813	1,341
Provision for chargebacks	4,224	0
Deferred tax liability-current portion, net	88	88
Deferred revenue, current portion	5,333	1,834
Total current liabilities	76,427	56,651
Contingent purchase consideration, net of current portion	19,193	15,278
Long-term indebtedness, net of current portion	251,000	62,000
Deferred tax liability long-term, net	0	1,419
Deferred revenue, net of current portion	1,632	0
Other liabilities	1,230	2,117
Total liabilities	349,482	137,465
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 37,885,227 shares issued and 37,472,274, shares outstanding at June 30, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013	38	37
Treasury stock, at cost, 412,953 common shares at both June 30, 2014 and December 31, 2013	(6,119)	(6,119)
Additional paid-in capital	260,778	247,637
Accumulated other comprehensive loss	(3,251)	(3,465)
Retained earnings	236,321	251,528
Total Emergent BioSolutions Inc. stockholders' equity	487,767	489,618
Noncontrolling interest in subsidiaries	0	(453)
Total stockholders' equity	487,767	489,165
Total liabilities and stockholders' equity	$ 837,249	$ 626,630